Australia’s Parliament Shoots Down Pharma Cost Recovery Bill; Lilly Closes In On Diabetes Reimbursement In NZ: Australia/New Zealand Regulatory Roundup
This article was originally published in PharmAsia News
PERTH, Australia - Medicines Australia applauded the defeat in Australia's parliament Aug. 28 of the National Health Amendment, which included a cost-recovery mechanism that would have put the onus on drug makers to fund the process for listing medicines on Australia's Pharmaceutical Benefits Scheme
You may also be interested in...
PERTH, Australia - New Zealand's Pharmaceutical Management Agency will now fund Johnson & Johnson's Concerta (methylphenidate extended release) for the treatment of attention deficit hyperactivity disorder, beginning Sept. 1
Medicines Australia Critical Of Labor Government's First Budget
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).